Cognition Therapeutics, Inc. Common Stock (CGTX)
Cognition Therapeutics, Inc. (CGTX) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, including Alzheimer's disease. The company's approach involves targeting molecular pathways involved in neurodegeneration to develop disease-modifying treatments. Founded with a focus on translating scientific discoveries into innovative medicines, Cognition Therapeutics aims to address unmet medical needs in cognitive disorders.
Company News
Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.
Cognition Therapeutics raised $30 million through a registered direct offering of 14.7 million common stock shares at $2.05 per share, with proceeds intended to support Phase 3 development of zervimesine for neurodegenerative disorders.
The Dow Jones index closed lower by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Blue Star Foods The Trade: Blue Star Foods Corp. (NASDAQ: BSFC) Director Nubar Herian acquired a total of 219,611 shares an average price of $0.14. To acquire these shares, it cost ...
Here is how Accelerate Diagnostics (AXDX) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.